InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' eq
Biotechnology, Pharmaceuticals
2026-09-18 4:45 PM EDT | Mentari Therapeutics, Inc.
Richards Group Inc. Announces September 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended September 30, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on September 29, 2026 and will be payable on October 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whethe
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-09-18 11:50 AM EDT | Richards Group Inc.
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-09-18 7:00 AM EDT | Theralase Technologies Inc.
Unbuzzd Wellness Announces Resignation of Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, the scientifically proven beverage formulated to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, announces that Richard Buzbuzian will resign from his position as Chief Executive Officer of the Company, effective October 1, 2026. The Company thanks Mr. Buzbuzian for his contributions and wishes him
2026-09-17 6:25 PM EDT | Unbuzzd Wellness Inc.
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce that it has closed its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and pre-funded common share purchase warrants of the Company ("Pre-Funded Warrants" and, together wit
2026-09-17 10:41 AM EDT | BetterLife Pharma Inc.
Nextleaf Announces Leadership Transition and Strategic Review; Sam Kassem Appointed Interim CEO
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), an innovation-driven Canadian cannabis processor, announces that Emma Andrews has stepped down as Chief Executive Officer, President and a director of the Company. The Board of Directors has appointed Sam Kassem, the Company's current Chief Financial Officer and a director of the Company, as Interim Chief Executive Officer
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-09-15 7:50 PM EDT | Nextleaf Solutions Ltd.
La Vie Health and Virotek Biosciences Partner to Advance the Next Generation of Precision Health
Ontario and Richmond Hill, Ontario--(Newsfile Corp. - September 15, 2026) - La Vie Health ("La Vie") and Virotek Biosciences ("Virotek") today announced a strategic collaboration to integrate advanced genomic insights into La Vie's broader physician-led preventative, precision and healthspan model. This partnership advances both companies' commitment to precision health, with Virotek adding a clinically contextualized genomic layer to La Vie's comprehensive precision-health prog
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-15 8:30 AM EDT | Virotek Biosciences Inc.
Extendicare Announces September 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - September 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of September 2026, which is payable on October 15, 2026 to shareholders of record at the close of business on September 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare
Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-15 8:00 AM EDT | Extendicare Inc.
Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Good Laboratory Practice ("GLP") toxicology analysis of intravenously administered Ru
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-09-15 7:00 AM EDT | Theralase Technologies Inc.
BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 15, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE:
Biotechnology, Pharmaceuticals, Health
2026-09-15 7:00 AM EDT | BioHarvest Sciences Inc.
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration (FDA).
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-14 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-1
Biotechnology, Pharmaceuticals, Health
2026-09-14 7:00 AM EDT | BioHarvest Sciences Inc.
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has filed a final short form prospectus (the "Final Prospectus") with the securities regulatory authorities in the provinces of British
2026-09-11 7:45 PM EDT | BetterLife Pharma Inc.
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte Ne
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-11 9:00 AM EDT | Phio Pharmaceuticals Corp.
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at
Biotechnology, Pharmaceuticals
2026-09-09 4:30 PM EDT | Mentari Therapeutics, Inc.
Herbal Dispatch Provides Update on Gold Royalty Interest in Artemis Gold's Blackwater Mine
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, today provided an update on a gold royalty interest held by the Company on mineral claims forming part of the Blackwater mine in central British Columbia. OVERVIEW OF THE ROYALTY Herbal Dispatch holds a royalty interest (the "Ro
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-09-09 1:01 AM EDT | Herbal Dispatch Inc.
Maxwell Biosciences Receives FDA Qualified Infectious Disease Product (QIDP) Designation for All-Cause Bacterial and Fungal Pneumonia
Austin, Texas--(Newsfile Corp. - September 8, 2026) - Maxwell Biosciences, a biotechnology company developing a new class of immune-inspired anti-infective therapeutics, today announced that on May 5, 2026, the U.S. Food and Drug Administration (FDA) granted Qualified Infectious Disease Product (QIDP) designation to MXB-22,510-SC, Maxwell's investigational parenteral injectable drug candidate for the treatment of community-acquired pneumonia (CAP) and hospital-acquired (HAP) or ventilator-ass
Biotechnology, Pharmaceuticals
2026-09-08 9:00 AM EDT | Maxwell Biosciences, Inc.
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Encinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience in ophthalmic drug development, clinical development and operations and regulatory strategy across Phase 1 through Phase 4 clinical trials. "Keith has substantial experience supporting U.
Biotechnology, Pharmaceuticals
2026-09-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Custom Health Completes Acquisition of Spencer Health Solutions, Bringing In-Home Medication Dispensing Technology Fully In-House
Effective September 4, 2026, Custom Health has completed its previously announced acquisition of Spencer Health Solutions, developer of the spencer® smart medication dispenser and in-home monitoring platform, giving the Company full ownership of the spencer® technology, intellectual property, and product roadmap. Spencer now operates as a wholly owned subsidiary of Custom Health, eliminating third-party support, infrastructure, and device costs previously incu
Technology, Pharmaceuticals, Health
2026-09-08 6:00 AM EDT | Custom Health Holdings Inc.
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company'
Biotechnology, Pharmaceuticals, Health
2026-09-08 3:15 AM EDT | Defence Therapeutics Inc.